Insight journal - Company

Cubist: Partnering activity 2009-2014

Posted on 13 March 2014

Tags: , ,

Cubist, a leading biopharmaceutical company focusses in the discovery, development and commercialization of novel acute care therapies. The big biotech company aims to be the market’s antibiotics leader and has been working on several compounds to address the unmet needs in the acute care environment.

Abstracted from: Report: Partnering Agreements with Cubist 2009-2014

Cubist, a top big biotech company, has made path breaking risks in the antibiotics market with its various partnerships and acquisitions. The company’s partnering activity is reviewed in the article.

The following figure shows the level of Cubist partnering deal announcements since 2009.

Figure 1: Cubist partnering deals 2009-2014

Figure 1: Cubist partnering deals 2009-2014

Figure 1: Cubist partnering deals 2009-2014

Source: Current Agreements, 2013

There has been a very steep decline in partnering after 2009. In the recent years, Cubist has raised money through loan financing and has enhanced its position in the market with strategic acquisitions. The company has a line of pipeline products and this could mean more partnering opportunities in the future.

Analysis of the partnering deals shows a strong emphasis on partnerships in infectious diseases. The company specifically works on bacterial diseases like Respiratory syncytial virus (RSV) and Methicillin-resistant Staphylococcus aureus (MRSA).

The following table provides an overview of the partnering deals announced by Cubist based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Report: Partnering Agreements with Cubist 2009-2014                                                                       

Figure 2: Cubist partnering deals by therapy area 2009-2014

 

Figure 2: Cubist partnering deals by therapy area 2009-2014

Figure 2: Cubist partnering deals by therapy area 2009-2014

Source: Current Agreements, 2013

Further analysis of these deals shows that Cubist has a preference for collaborative R&D, co promotion, licensing and marketing deals, similar to many other top pharmaceutical or big biotech companies. Such partnering deals provide the right for Cubist to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.

The following table provides an overview of the partnering deals announced by Cubist based on deal type disclosed.

Figure 3: Cubist partnering deals by deal type 2009-2014

 

Figure 3: Cubist partnering deals by deal type 2009-2014

Figure 3: Cubist partnering deals by deal type 2009-2014

Source: Current Agreements, 2014

When looking at stage of development at partnering deal signing, the most popular stage at signing is marketed with 7 deal announcements, followed closely by discovery stage deal announcements.

Cubist is also active in partnering at preclinical and phase II deals. Such deals are of on-going importance to all top biopharma companies as they seek to bolster their pipeline, fill gaps left as a result of drug candidates failing during clinical development, and ensure they have replacement products for when key drugs come off patent.

The following table provides an overview of the partnering deals announced by Cubist based on stage of development at signature.

Figure 4: Cubist partnering by stage of development 2009-2014

 

Source: Current Agreements, 2014 When looking at stage of development at partnering deal signing, the most popular stage at signing is marketed with 7 deal announcements, followed closely by discovery stage deal announcements.  Cubist is also active in partnering at preclinical and phase II deals. Such deals are of on-going importance to all top biopharma companies as they seek to bolster their pipeline, fill gaps left as a result of drug candidates failing during clinical development, and ensure they have replacement products for when key drugs come off patent.  The following table provides an overview of the partnering deals announced by Cubist based on stage of development at signature.  Figure 4: Cubist partnering by stage of development 2009-2014

Source: Current Agreements, 2014 

 

Source: Current Agreements, 2014

Cubist has signed over 20 partnering, collaborative R&D and licensing deals since 2009. The following provides a summary of the top deals by headline value.

Figure 5: Top Cubist partnering deals by headline value 2009-2014

 

 Figure 5: Top Cubist partnering deals by headline value 2009-2014

Figure 5: Top Cubist partnering deals by headline value 2009-2014

Source: Current Agreements, 2014

Our report provides more detailed insight into the details of each deal. See: Report: Partnering Agreements with Cubist 2009-2014

Cubist partnering at Current Agreements

View all partnering deals for Cubist: 2014 | 2013 | 2012 | 2011 | 2010 | 2009

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Report: Partnering Agreements with Cubist 2009-2014

More 

Summary profile data for Cubist

Partnering interests for Cubist 

M&A activity for Cubist

 

Available reports from Current Partnering

Report: Partnering Agreements with Cubist 2009-2014

Report: Partnering Deals and Alliances with Big Biotech

 

Available resources for deal coverage for Cubist          

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Cubist company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
rauconbadgejpg
e78banner300x150animgif